Endoglin, Y-box binding protein 1, SRY-box transcription factor 2, Cadherin 3, and Double minute 2 protein (ENG/YBX1/SOX2/CDH3/MDM2)

This target entry refers to a specific panel of five tumor-associated antigens (TAAs) utilized in multi-peptide immunotherapy: Endoglin (ENG), Y-box binding protein 1 (YBX1), SRY-box transcription factor 2 (SOX2), Cadherin 3 (CDH3), and Double minute 2 protein (MDM2). Endoglin is a TGF-beta co-receptor critical for tumor angiogenesis (UniProt P17813), while YBX1 and SOX2 are transcription-related factors that drive cell proliferation and maintain cancer stem cell pluripotency (UniProt P67809, P48431). Cadherin 3 (P-cadherin) facilitates cell-cell adhesion and is linked to increased metastatic potential (UniProt P22223), and MDM2 acts as a primary negative regulator of the p53 tumor suppressor through its E3 ubiquitin ligase activity (UniProt Q00987). These proteins are frequently co-expressed in various solid tumors, particularly colorectal cancer, making them attractive targets for combined therapeutic intervention. The primary clinical application for this specific combination is the OncoMimic vaccine EO2040, which uses bacterial peptides to induce a cross-reactive T-cell response against these human antigens (Enterome, 2021; NCT04639193). By targeting five distinct pathways simultaneously, this approach seeks to minimize the risk of tumor immune escape and enhance therapeutic efficacy in patients with microsatellite instability-high (MSI-H) cancers.

Other names

CD105YB-1P-cadherinHDM2OncoMimic Target Panel

The primary mechanism of action for drugs targeting this panel, such as the therapeutic vaccine EO2040, is the induction of a memory T-cell response through the administration of microbiome-derived peptides (OncoMimics) that cross-react with these specific tumor-associated antigens. Individual components may also be targeted by monoclonal antibodies (e.g., Endoglin) to inhibit angiogenesis or small molecules (e.g., MDM2) to restore p53-mediated apoptosis.